The Hepatitis Fund is a new Swiss Foundation created in 2019 to consolidate the EndHep2030 project sponsored by Rockefeller Philanthropy Advisors.
The Hepatitis Fund is led by a Governing Board composed from Mr. Wangsheng Li (ex. Zeshan Foundation), Mr Charles Gore (Medicines Patent Pool) and Mr Etienne Gard (Bratschi AG). The foundation will continue the mission of EndHep2030 and provide catalytic funding for viral hepatitis elimination in low-and-middle income countries. The foundation is guided by an Advisory Board of viral hepatitis experts. The Hepatitis Fund has created headquarters in Geneva in 2020, and its operations have started, albeit delayed by the consequences of the COVID-19 pandemic.
Conceived in collaboration with the World Health Organization, U.S. Centers for Disease Control and Prevention, and many other partners, the EndHep2030 project was incubated by ZeShan Foundation with operating support in 2016–2020 and a seed grant to The Hepatitis Fund.
Initial funding and in-kind support has also been provided by the CDC Foundation, John C. Martin Foundation, the Robert Wood Johnson Foundation, Rockefeller Philanthropy Advisors and individual donors.
The statutes of the foundation can be consulted on Geneva Trade Registry.